1378026-80-2

Upstream product

• 300726-25-4 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)-1-phenylethanone 
• 98-86-2 acetophenone 

Downstream Products

• 1378026-81-3 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[4-{5-(2-oxo-2-phenylethylthio)-1,3,4-thiadiazol-2-yl}piperazin-1-yl]-4-oxoquinoline-3-carboxylic acid 
• 1378026-82-4 1-ethyl-6-fluoro-1,4-dihydro-7-[4-{5-(2-oxo-2-phenylethylthio)-1,3,4-thiadiazol-2-yl}piperazin-1-yl]-4-oxoquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and antibacterial, antimycobacterial and docking studies of novel N-piperazinyl fluoroquinolones

The present study deals with the synthesis of some novel fluoroquinolone derivatives as antibacterial and antitubercular agents. The titled compounds 7a-g and 8a-g were found to possess comparable or more potent activity than the reference compounds ciprofloxacin, norfloxacin, isoniazid and rifampicin. The synthesized compounds showed activity against S. aureus and C. bacterium, whereas poor activity was observed against P. aeruginosa and E. coli. These compounds were subjected to in vitro cytotoxicity study by MTT assay, and their selectivity index was calculated. Compound 7d was found to be the most efficient antimycobacterial agent amongst the series. Molecular docking revealed that synthesized derivatives and target proteins were actively involved in a binding pattern and had significant correlation with biological activity. Graphical abstract: Novel N-piperazinyl fluoroquinolone derivatives were synthesized and evaluated for their in vitro antibacterial, antimycobacterial and cytotoxic properties. Activity results were compared with the docking results. [Figure not available: see fulltext.]